Navigation Links
Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial
Date:9/12/2008

SYDNEY, Australia, Sept. 12 /PRNewswire/ -- Sunshine Heart (ASX: SHC), a global medical device company focused on innovative heart assist technologies, today announced that it has received conditional approval of an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin its first U.S. clinical feasibility trial for the C-Pulse(TM) device in patients with moderate heart failure. C-Pulse is an implantable aortic cuff, designed as a cost effective heart assist therapy. The device is a uniquely positioned Class III heart failure therapy that offers an innovative intervention bridging the clinical gap between heart failure pacemakers and end stage therapies which potentially creates a new market opportunity.

Enrollment is expected to begin at six premiere U.S. medical institutions by the end of 2008. The objective of the trial is to evaluate the safety and efficacy of C-Pulse in 20 patients currently suffering from moderate heart failure. William Abraham, MD, of Ohio State University, and Patrick McCarthy, MD, of Northwestern University Medical Center, will serve as national co-lead principal investigators. Each patient's performance with C-Pulse will be closely monitored over a six month follow-up period.

Following the trial's successful completion, the Company will request CE Mark approval to market C-Pulse in the E.U. and other international countries that honor CE Mark label claims for device safety. In addition, the Company will seek FDA approval for a larger randomized U.S. pivotal study to support the submission of a marketing application for C-Pulse in the U.S.

Malcolm McComas, Chairman of the Board commented, "We are proud to announce that Sunshine Heart is the first company to receive FDA approval to run a clinical trial evaluating a non-blood contacting heart assist device. The agency's clinical approval of this treatment approach for moderate heart failure raises Sunshine Heart's profile as a global development stage medical device company supported by internationally renowned trial centers and lead investigators."

Donald Rohrbaugh, Chief Executive Officer, said, "We are very encouraged by the FDA's IDE approval for C-Pulse and look forward to generating additional data from this study to support our global regulatory strategy. Our C-Pulse heart assist therapy offers a unique treatment to patients who are suffering from moderate heart failure and represents an important advancement in addressing this significant unmet clinical need. If left untreated, moderate heart failure is a debilitating disease that can lead to premature death. We believe that C-Pulse represents one of the most innovative therapies in development for this indication in patients who no longer receive symptom relief from medication or cardiac synchronization pacemakers. With more than five million people suffering from heart failure today and a half million more diagnosed each year, we are extremely confident in the advantages C-Pulse provides to patients as a simple, safe, less invasive, non-blood contacting implant option."

About Sunshine Heart

Sunshine Heart (ASX: SHC) (http://www.sunshineheart.com) is a global medical device company, committed to the commercialization of C-Pulse(TM) an implantable, non-blood contacting, heart assist therapy for the treatment of people with heart failure. Through the use of counterpulsation technology, C-Pulse(TM) is designed to increase cardiac output while reducing the heart's workload for ventricular loading. Sunshine Heart listed on the ASX in September 2004 has a presence in Australia, New Zealand and the United States of America.

For further information, please visit http://www.sunshineheart.com or contact:

Sunshine Heart: Investor Relations:

Don Rohrbaugh R.J. Pellegrino

Chief Executive Officer The Ruth Group

+1 714 259 0732 646-536-7009

don.rohrbaugh@sunshineheart.com rpellegrino@theruthgroup.com

Media:

Janine McCargo

The Ruth Group

646-536-7033

jmccargo@theruthgroup.com

Forward Looking Statements

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties from time to time in the Company's filings with the Australian Securities Exchange.


'/>"/>
SOURCE Sunshine Heart
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Many Heart Attack Patients Dont Get Best Emergency Treatment
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
4. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
5. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
6. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
7. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
8. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
9. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
10. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
11. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  A new study by a pair ... of opioid therapy to treat chronic pain is not ... more harmful consequences, including death. Palliative care ... Zankhana Mehta , M.D., authored the study which provides ... therapy. The study was published in the December 2016 ...
(Date:12/8/2016)... 2016 Mederi Therapeutics Inc . hat die behördliche Zulassung ... für gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast ... of Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... , December 8, 2016 According ... Diabetes Injection Pens Market is expected to be worth ... US$4.9 bn in 2015. Between the forecast years of 2016 ... a CAGR of 7.9%. The leading players operating in the ... Lilly and Company, AstraZaneca plc., Biocon Ltd., and Sanofi S.A. ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, the ... and consumer health products, today announced that it had joined the Pharmaceutical Supply ... non-profit organization to unite pharmaceutical and healthcare companies that share a vision of ...
(Date:12/8/2016)... Ga (PRWEB) , ... December 08, 2016 , ... ... as soon after surgery as possible. With this in mind, SIGVARIS has created ... (DVT or blood clot) during bed rest and provide the benefits of graduated ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... financial planning services from offices headquartered in Hamilton County, is embarking on a ... , LuvFurMutts specializes in finding new homes for orphaned or neglected senior dogs ...
(Date:12/8/2016)... , ... December 08, 2016 , ... The Compretta Insurance ... and residential clients in and around the Hancock County area, is announcing the launch ... County Food Pantry. , The Hancock County Food Pantry has worked for more than ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... will have the unique opportunity to get hands-on experience in an emergency medical ... an immersive experience to gain invaluable, real-life medical skills that are critical success ...
Breaking Medicine News(10 mins):